Opening a pharmaceutical company requires navigating one of the most heavily regulated industries in the world, but the barrier to entry is lower than most people assume. You don’t necessarily need a factory, a chemistry lab, or billions in capital. What you do need is a clear business model, regulatory registrations, quality systems, and enough funding to cover the long runway before revenue starts flowing. Here’s how the process works from the ground up.
Choose a Business Model First
The single biggest decision you’ll make early on is whether your company will manufacture drugs itself or outsource production entirely. These are fundamentally different businesses with different capital requirements, timelines, and risk profiles.
If you build or lease your own manufacturing facility, you’re looking at tens of millions of dollars in buildout costs, specialized equipment, cleanroom environments, and a large staff of trained operators and quality personnel. You’ll also need to pass FDA inspections before you produce a single pill. This is the traditional path, and it gives you the most control over your product and supply chain.
The alternative is a “virtual” or asset-light model. In this setup, your company owns the intellectual property, manages the regulatory filings, and handles commercialization, but the actual manufacturing is done by contract development and manufacturing organizations (CDMOs). These third-party facilities already have FDA-compliant operations in place. You pay them to produce your product under your specifications. This model dramatically reduces startup capital and lets you focus on research, formulation, or marketing rather than running a plant. Many newer pharmaceutical companies operate this way, and the model has become increasingly common because of its speed and efficiency.
A third option sits between these two: you can start as a repackager or relabeler, purchasing bulk drugs from approved manufacturers and packaging them under your own label. This is common in the generic drug space and has a faster path to market, though margins are thinner.
Form the Legal Entity and Secure Licensing
Before touching anything pharmaceutical, you need a properly structured business entity. Most pharmaceutical companies incorporate as a C-corporation because of the liability protections and the ability to issue different classes of stock to investors. Your state of incorporation matters for tax and regulatory reasons, and you’ll need a registered agent in every state where you do business.
State-level licensing comes next. Every state has its own pharmacy board or department of health that issues manufacturer, distributor, or wholesaler licenses depending on your operations. These are separate from federal requirements and vary significantly. Some states require a licensed pharmacist on staff. Others require facility inspections before granting a license. Budget several months for state licensing alone, because many boards move slowly and have backlogs.
If you plan to handle controlled substances at any point, you’ll also need a DEA registration, which involves its own application process, background checks, and security requirements for your facility.
Register With the FDA
Federal law requires all domestic drug manufacturers, repackers, relabelers, and salvagers to register each establishment with the FDA. You must register within five calendar days of beginning operations. Foreign establishments must register before any product is imported into the United States.
Registration is done electronically through the FDA’s system and requires detailed information: the names of all owners, partners, or corporate officers and directors; the physical address and phone number of each facility; a Unique Facility Identifier; and a description of all operations performed at each site. You’ll also need to designate an official contact person. The FDA charges an annual establishment registration fee, which for drug manufacturing facilities runs into the hundreds of thousands of dollars under the user fee program.
Registration alone doesn’t mean you’re approved to sell anything. It simply puts the FDA on notice that your facility exists. You’ll also need to list every drug product you manufacture, which is a separate but related requirement filed through the same electronic system. Each product gets a National Drug Code, a unique identifier that follows it through the supply chain.
Meet Current Good Manufacturing Practice Standards
If you’re manufacturing in-house, your facility must comply with Current Good Manufacturing Practice (cGMP) regulations, codified in Title 21 of the Code of Federal Regulations, Parts 210 and 211. These aren’t suggestions. They’re legally enforceable minimum requirements for the methods, facilities, and controls used in manufacturing, processing, and packaging drug products.
In practical terms, cGMP covers everything: the design and maintenance of your building, the calibration and cleaning of equipment, the qualifications and training of personnel, how raw materials are tested and released, how production batches are documented, how finished products are tested before distribution, and how you investigate and respond to any deviation from your procedures. Every step in the manufacturing process must be documented in writing, and every batch must be traceable from raw ingredients to the finished package.
FDA assessors and investigators will inspect your facility to determine whether you have the necessary equipment, procedures, and capability to manufacture the drugs you intend to market. Failing a cGMP inspection can result in warning letters, import alerts, or injunctions that shut down production entirely. Many companies hire cGMP consultants during the buildout phase to design the facility and quality systems correctly from the start, which is far cheaper than retrofitting after a failed inspection.
If you’re using a CDMO, the manufacturing partner handles cGMP compliance at their facility, but you remain responsible for ensuring they meet the standards. You’ll need quality agreements in place and should audit your contract manufacturers regularly.
Build a Quality Management System
A quality management system (QMS) is the backbone of any pharmaceutical operation. It’s the formalized structure of processes, procedures, and responsibilities that ensures every product meets its specifications and every problem gets caught and corrected.
At minimum, your QMS needs to include document control (so that everyone works from the current version of every procedure), change control (so that no modification to a process, material, or specification happens without review and approval), and a corrective and preventive action program, commonly called CAPA. CAPA is the mechanism by which you investigate deviations, identify root causes, implement fixes, and verify those fixes actually work. Regulators pay close attention to your CAPA system because it reveals whether your company learns from its mistakes.
Beyond these core elements, your QMS should cover supplier qualification, training and competency tracking, internal audits, complaint handling, product recalls, and management review. The system should generate metrics that leadership reviews regularly, not just to satisfy inspectors but to catch quality trends before they become crises. Building this system from scratch takes time, and many startups underestimate the effort involved. Plan for six to twelve months of development before your QMS is fully operational.
Understand the Drug Approval Pathway
Registering your company and building a compliant facility are prerequisites, but they don’t authorize you to sell a drug. The product itself needs its own approval.
If you’re developing a new drug, you’ll file an Investigational New Drug application to begin clinical trials, then work through Phase 1, 2, and 3 trials before submitting a New Drug Application. This process typically takes 10 to 15 years and costs hundreds of millions of dollars, which is why most startups in this space rely heavily on venture capital or partnership deals with larger companies.
If you’re entering the generic drug market, the pathway is shorter and cheaper. You file an Abbreviated New Drug Application, which requires you to demonstrate that your product is bioequivalent to an already-approved reference drug. You still need a compliant facility and robust quality systems, but you skip the lengthy clinical trials. Generic drug companies can reach market in two to four years from the start of development.
A third pathway exists for over-the-counter drugs marketed under an FDA monograph. These products don’t require individual approval if they conform to the monograph’s specifications for active ingredients, dosages, and labeling. This is the fastest route to market but limits you to well-established product categories.
Plan for Environmental Compliance
Pharmaceutical manufacturing generates hazardous waste, and the EPA regulates how you handle it. Any waste that is ignitable, corrosive, reactive, or toxic falls under hazardous waste rules. You cannot dispose of hazardous waste pharmaceuticals down any drain, whether that’s a sink, toilet, or floor drain connected to a public sewer system.
Your facility will need a waste management plan that classifies every waste stream, establishes proper containment and labeling, and arranges for licensed hazardous waste haulers to transport materials to approved disposal facilities. Depending on the volume of waste you generate, you may be classified as a small quantity or large quantity generator, each with different storage time limits and reporting requirements. State environmental agencies often layer additional rules on top of federal ones, so check your state’s requirements early in the facility planning process.
Secure Funding and Insurance
Pharmaceutical startups are capital-intensive regardless of the business model. A virtual company outsourcing to CDMOs might need $5 to $20 million to get a generic product to market, while a company building its own manufacturing and developing a novel drug could burn through $100 million before seeing any revenue. Common funding sources include venture capital, private equity, government grants (especially through BARDA or NIH programs for certain therapeutic areas), and strategic partnerships with established pharma companies.
Insurance is non-negotiable. Product liability coverage protects you against claims that your drug caused harm. The life sciences insurance market in 2025 is relatively stable, with rate increases in the low single digits (around 3 to 5 percent) for companies with clean track records. If you’re running clinical trials, you’ll need clinical trial liability coverage, which includes a sublimit for medical expenses related to study participants. Ethics committees in many countries require proof of this coverage before they approve your trial protocol, and requirements vary by jurisdiction.
Beyond product liability, you’ll need general liability, property insurance for your facility and equipment, workers’ compensation, directors and officers coverage, and potentially cyber liability insurance given the sensitive data pharmaceutical companies handle. Working with a broker experienced in life sciences is important because standard commercial policies often exclude pharmaceutical manufacturing risks.
Hire the Right Team Early
Regulatory agencies don’t just inspect facilities. They evaluate whether your personnel are qualified to do what they claim to be doing. At a minimum, you’ll need a head of quality (often called a Quality Assurance Director), a regulatory affairs lead who manages FDA submissions and state licensing, and a qualified person responsible for releasing each batch of product. If you’re manufacturing, you’ll need production managers, lab analysts, and maintenance staff trained on your specific equipment.
For a virtual company, the team is leaner but still specialized. You need someone who can manage CDMO relationships and audit their facilities, a regulatory strategist, and commercial expertise to navigate drug pricing, distribution, and payer relationships. Many founders come from the pharmaceutical industry and bring deep networks, which matters because this is an industry where relationships with regulators, distributors, and contract partners directly affect your speed to market.